DOKTOR FALK FARMA GMBKH, PREDSTAVITELSTVO
🇷🇺Russia
Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 343
- Registration Number
- NCT00747110
- Locations
- 🇩🇪
Klinikum St. Marien, Amberg, Germany
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 648
- Registration Number
- NCT00746447
- Locations
- 🇩🇪
Evangelisches Krankenhaus Kalk, Medical Dept., Cologne, Germany
Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)
Phase 3
Terminated
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 62
- Registration Number
- NCT00746486
- Locations
- 🇩🇪
Universitätsklinikum Bonn, Bonn, NRW, Germany
🇫🇷Hôpital Saint-Antoine, Paris, France
Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 345
- Registration Number
- NCT00695643
- Locations
- 🇩🇪
Evang. Krankenhaus Kalk, Medical department, Cologne, Germany
Pharmacokinetic Investigation of UDCA in Bile and Serum
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Registration Number
- NCT00529009
- Locations
- 🇳🇱
Beuers, Amsterdam, Netherlands
Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis
Phase 3
Completed
- Conditions
- Collagenous Colitis
- Interventions
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 92
- Registration Number
- NCT00450086
- Locations
- 🇩🇪
Center of digestive diseases, Hamburg, Germany
OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis
Phase 3
Completed
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 380
- Registration Number
- NCT00449722
- Locations
- 🇩🇪
Evangelisches Krankenhaus Kalk, Cologne, Germany
Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 311
- Registration Number
- NCT00300118
- Locations
- 🇩🇪
Ev. Krankenhaus Hattingen GmbH, Hattingen, Germany
© Copyright 2025. All Rights Reserved by MedPath